Neural computing, a subset of artificial intelligence, mirrors the intricate workings of the human brain by employing interconnected nodes, or neurons, to process and transmit information. These neural networks, composed of layers of nodes, meticulously analyze input data through successive operations, enabling them to discern patterns and relationships crucial for tasks such as classification, prediction, and pattern recognition. What sets neural computing apart is its ability to learn from examples via a process known as training, where networks adjust their internal parameters iteratively to minimize disparities between predicted and actual outputs. This adaptability renders neural networks versatile across various domains, from image and speech recognition to medical diagnosis and financial forecasting. Despite their efficacy, neural networks confront challenges, notably their voracious appetite for data during training and computational intensity, particularly in intricate architectures. Additionally, the "black box" problem persists, hindering transparency and accountability in crucial applications. Nonetheless, ongoing advancements in neural computing, fueled by research in machine learning and hardware innovation, hold promise for overcoming these hurdles and unlocking new vistas in artificial intelligence.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States